When the weather gets cold after entering winter, it may face the risk of mutual or co-epidemic of COVID-19, influenza and other respiratory infectious diseases, which will bring a new round of respiratory infectious disease infection peak, so it is urgent to prevent it in advance.
According to the report of China CDC, since 2023, the proportion of XBB mutants and their subfamilies in China has gradually increased, reaching 99% by the end of August. XBB series mutant is a kind of recombinant mutant in Omicron, and its spreading ability and immune escape ability are stronger than those of Omicron mutant which was popular in the early stage, so it is a global dominant strain at present.
Photo courtesy of the enterprise, issued by Yangguang. com
At the end of July, 2023, the State Council issued the Work Plan for Vaccination of Key Population in Covid-19 in the Near Future (hereinafter referred to as the Vaccination Plan) in response to the joint prevention and control mechanism of novel coronavirus infection. The Vaccination Plan clearly states that during the epidemic period of XBB mutant in Covid-19, especially in autumn and winter this year, it is recommended to vaccinate the vaccine containing XBB mutant antigen. The recombinant trivalent XBB Covid-19 trimer protein vaccine (Sf9 cells) developed by WEISKE Bio/Sichuan University Huaxi-VIKEXIN trivalent XBB vaccine has been officially launched in many places in China recently.
Photo courtesy of the enterprise, issued by Yangguang. com
The research shows that XBB mutant has strong immune escape ability and is prone to breakthrough infection, and the key population such as the elderly population is more harmful after being infected with XBB mutant. The "Vaccination Plan" points out that people aged 60 and above who have completed basic immunization or have been infected with Covid-19, or people aged 18-59 who have serious basic diseases, people with low immune function, and people with high risk of infection (including: civil affairs, health care, education, housing construction, transportation, public security, justice, state-owned assets, finance, market, cultural tourism, industrial letter, commerce, science and technology, people and society)
Photo courtesy of the enterprise, issued by Yangguang. com
In July this year, the State Council Joint Prevention and Control Mechanism promulgated the "Vaccination Plan", and the trivalent XBB vaccine of Wickham has been included in emergency use in a certain range, which can be used for vaccination of key populations in the near future. This vaccine is the world’s first broad-spectrum COVID-19 vaccine developed by West China of Sichuan University in conjunction with Wesker Biological Team to effectively prevent diseases caused by Covid-19 XBB.1.5 and other variants, and can effectively prevent diseases caused by current XBB and other variants Covid-19.
It is reported that at present, the 3-valent XBB vaccine of Wickham has been delivered, and will arrive at many CDC and inoculation units in the country one after another. Citizens who meet the inoculation conditions can consult the relevant CDC and inoculation units to make an appointment for vaccination.
Photo courtesy of the enterprise, issued by Yangguang. com
Accurate and powerful, better security.
Wickham trivalent XBB vaccine is a high-purity and high-quality trivalent mutant recombinant protein vaccine produced by Wesker Bio, which takes advantage of the rapid response of the international advanced insect cell technology platform to produce recombinant protein vaccine. Aiming at the spike protein receptor binding domain (S-RBD) and heptapeptide repeat domain (HR) of COVID-19 mutants such as XBB, the vaccine is prepared by accurately designing subunit vaccine antigen based on structure, self-assembling into stable protein particles with trimer structure, purifying and mixing, and adding oil-in-water emulsion adjuvant based on squalene. The innovative adjuvant greatly improved the titer of neutralizing antibody of the vaccine, and made the trimer protein vaccine induce a stronger T cell immune response in vivo.
The clinical trial data showed that the trivalent XBB vaccine of Vikexin could induce high-level neutralizing antibodies against the mutant strains such as XBB.1, XBB.1.5, XBB.1.16, XBB.1.9.1, EG.5, XBB.2.3, BA.5, etc., with good safety, which is of great significance to prevent the infection of mutant strains and reduce the severe disease rate and mortality rate.
It is reported that since May, 2023, the World Health Organization (WHO), the US Food and Drug Administration (FDA), the European Center for Disease Control and Prevention (ECDC) and the European Medicines Agency (EMA) have successively made suggestions on updating the composition of the vaccine in COVID-19 in 2023, and proposed that the new vaccine should induce neutralizing antibody reaction against the XBB mutant, the mainstream strain in COVID-19. WHO suggests that the elderly, young people with severe complications (such as diabetes and heart disease), people with low immune function and frontline health workers should be given priority to receive COVID-19 vaccine against XBB mutant.
In September, 2023, the Centers for Disease Control and Prevention (CDC) officially updated and recommended the XBB mutant COVID-19 vaccine in the United States, suggesting that people over 6 months in the United States should be vaccinated with the upgraded COVID-19 vaccine with XBB.1.5 as antigen in autumn and winter of 2023. According to US government data, as of mid-November, about 36 million adults have been vaccinated with the latest COVID-19 vaccine, which means that 13.9% of adults have been vaccinated with the upgraded XBB COVID-19 vaccine in the two months since the XBB vaccine was launched in the United States.
References:
1. the epidemic situation of infection in novel coronavirus in China. China center for disease control and prevention network.2023,9.https://www.chinacdc.cn/jkzt/CRB/ZL/szkb _ 11803/jszl _ 13141/202309/t20230906 _ 269361.html.
National COVID-19 Infection Epidemic Situation. Chinese Center for Disease Control and Prevention website. 2023, 9.https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202309/t20230906_269361.html
2.Callaway, E. COVID’s future: mini-waves rather than seasonal surges. Nature. 2023, 5. pp. 229？ 230
3. Bowe, Benjamin, et al. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nature Medicine. 2022,11. pp. 2398-2405
4.WHO. SAGE updates COVID-19 vaccination guidance. SAGE updates COVID-19 vaccination guidance ( who.int )
5.Statement on the antigen composition of COVID-19 vaccines.WHO. 2023,5. https:// www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines
6.EMA and ECDC statement on updating COVID-19 vaccines to target new SARS-CoV-2 virus variants.EMA.2023, 7. https:// www.ema.europa.eu/ en/news/ ema-ecdc- statement- updating-covid-19-vaccines-target-new-sars-cov-2-virus-variants
7. Product description of recombinant trivalent Covid-19 (XBB+BA.5+Delta mutant) trimer protein vaccine (Sf9 cell).
Package insert of Recombinant COVID-19 Trivalent (XBB + BA.5 + Delta) Protein Vaccine (Sf9 Cell)
(Note: This article belongs to the commercial information published by Yangguang. com, and the content of the article does not represent the views of this website, and it is for reference only)